Marci Harter

Marci Harter is a Senior Principal Scientist in Toxicology at AbbVie since August 2024, previously holding the same title at Cerevel Therapeutics from November 2022 to August 2024, where responsibilities included defining and executing nonclinical safety strategies aligned with project objectives. Prior to that, Marci served as Principal Research Scientist and Senior Research Scientist in Safety Pharmacology at Charles River Laboratories from August 2017 to November 2022, overseeing over 350 preclinical studies and integrating safety pharmacology endpoints into toxicology studies. Marci began a career in safety pharmacology at MPI Research, rising from Research Associate to Study Director from November 2003 to August 2017, managing study planning and execution in compliance with regulatory guidelines. Educational qualifications include a Bachelor of Science in Biological and Biomedical Sciences from Western Michigan University and an Associate of Science in Biology from Glen Oaks Community College.